Galvanize Therapeutics

Notes

Galvanize Therapeutics is a medical device company developing pulsed electric field (PEF) ablation technology for treating cancer and chronic lung diseases. The company's ALIYA Pulsed Electric Field Ablation System is designed to precisely ablate tissue while preserving surrounding critical structures.

The PEF technology uses short, high-voltage electrical pulses to create nanopores in cell membranes, leading to cell death while potentially sparing extracellular structures like blood vessels and airways. This approach may offer advantages over thermal ablation techniques in treating tumors near critical structures.

Galvanize has received FDA Breakthrough Device Designation for its lung cancer ablation system and is conducting clinical studies. The technology is also being developed for applications in treating other solid tumors and chronic obstructive pulmonary disease (COPD).

Team

• Adam Levy - CEO
  • LinkedIn: linkedin.com/in/adam-levy-galvanize
• Experienced leadership team from medical device industry

Additional Research Findings

• Founded in 2017, based in Redwood City, CA
• FDA Breakthrough Device Designation for lung cancer
• ALIYA Pulsed Electric Field Ablation System
• Clinical trials ongoing for lung tumor ablation
• Technology preserves critical structures near tumors
• Also developing for COPD treatment
• Backed by major medical device and venture investors
• Raised significant venture capital funding

Sources

• Galvanize Therapeutics Website
• LinkedIn Company Page
• ClinicalTrials.gov
• FDA Breakthrough Device Designation